TCGA-34-2600-01A-01R-0851-07
— · cohortSQ1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ1
- subtype
- cohortSQ1
- age_years
- 76
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- NOTCH_SIGNALING+0.260
- P53_PATHWAY+0.150
- WNT_BETA_CATENIN_SIGNALING+0.150
- G2M_CHECKPOINT+0.120
- APICAL_SURFACE+0.110
- MYC_TARGETS_V1+0.110
- MYC_TARGETS_V2+0.110
- KRAS_SIGNALING_DN+0.090
- SPERMATOGENESIS+0.070
- DNA_REPAIR+0.040
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.560
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.550
- INTERFERON_ALPHA_RESPONSE-0.550
- IL6_JAK_STAT3_SIGNALING-0.540
- INTERFERON_GAMMA_RESPONSE-0.520
- INFLAMMATORY_RESPONSE-0.500
- ANGIOGENESIS-0.450
- COMPLEMENT-0.430
- IL2_STAT5_SIGNALING-0.360
- KRAS_SIGNALING_UP-0.360
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-0511 | Med | Medulloblastoma | 0.884 |
| 2 | 20040095.TNBC | — | E | 0.884 |
| 3 | 67da6843-b0fe-4ff9-8cef-a66e606c8f54 | — | — | 0.873 |
| 4 | TCGA-56-A4BX-01A-11R-A24H-07 | — | cohortSQ2 | 0.873 |
| 5 | SRR8518365 | — | E | 0.866 |
| 6 | SRR8518307 | — | D | 0.860 |
| 7 | ERR2208946 | — | — | 0.853 |
| 8 | MDT-AP-0337 | Med | Medulloblastoma | 0.852 |
| 9 | TCGA-E2-A105-01A-11R-A10J-07 | — | B | 0.850 |
| 10 | R230 | — | — | 0.845 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 14 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| NOTCH_SIGNALING | 0.260 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.150 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.150 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.120 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.110 | Temsirolimus | — uncovered |
| MYC_TARGETS_V1 | 0.110 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.110 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.090 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.070 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.040 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.020 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.020 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.020 | Cobimetinib | — uncovered |
| UV_RESPONSE_UP | 0.020 | Idelalisib | — uncovered |